健帆生物(300529.SZ):奮鬥者一號員工持股計劃購買完成
格隆匯9月8日丨健帆生物(300529.SZ)公佈,截至本公吿日,公司奮鬥者一號員工持股計劃通過二級市場以集中競價交易方式累計買入公司股票5,642,150股,佔公司總股本的0.70%,成交總金額為13,816.82萬元人民幣,成交均價為24.49元/股。至此,公司奮鬥者一號員工持股計劃已完成股票購買,上述股票將按照規定予以鎖定,法定鎖定期為12個月,自公司公吿最後一筆標的股票完成購買之日起計算。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.